Foundation to Advance Vascular Cures Announces Dr. Ebony Dashiell-Aje as a New Member of the Board of Directors

March 11, 2025

The Foundation to Advance Vascular Cures is delighted to announce the appointment of Dr. Ebony Dashiell-Aje to its Board of Directors. Dr. Dashiell-Aje brings a wealth of expertise in patient-centered outcomes research, measurement science, and patient engagement, making her an invaluable addition to our mission of advancing vascular health solutions.

Currently, Dr. Dashiell-Aje serves as the Executive Director and Head of Patient-Centered Outcomes Science at BioMarin, where she has demonstrated exceptional leadership in developing and implementing patient-focused research strategies. Her rapid advancement from Director to Executive Director in just over two years underscores her ability to drive meaningful progress in patient-centered healthcare initiatives. 

Dr. Dashiell-Aje's previous experience at the FDA's Division of Clinical Outcome Assessment (DCOA) in the Office of New Drugs has provided her with unique insights into both regulatory processes and the science of patient input to address unmet medical needs. As a scientific lead and consultant to CDER, CBER, and CDRH, she played a critical role in shaping patient-focused drug development (PFDD) policy efforts and evaluating new therapeutic solutions.

With a PhD in Human Development from the University of Maryland, College Park, Dr. Dashiell-Aje combines a strong academic foundation with extensive practical experience. As a health outcomes researcher and methodologist, she is driven by a passion for public health and promoting patient-focused medical product development and clinical care. Over the years, she has led teams to implement scalable, scientifically rigorous patient-centered research strategies to drive regulatory and commercial success. As a result, her expertise has significantly contributed to evidence-based solutions and has shaped health policy across various research environments.

Dr. Dashiell-Aje brings not only her expanded industry experience but also the valuable perspective gained during her previous tenure with The Foundation to Advance Vascular Cures from 2019 to 2020. We are especially excited about how her enhanced leadership experience and deeper insights into patient-centered outcomes will strengthen our strategic initiatives and expand our impact in the healthcare community. 

Her expertise will be particularly valuable in advancing patient-centered research initiatives, providing strategic guidance on regulatory matters, strengthening our measurement science methodologies, and enhancing our engagement with healthcare stakeholders. These areas of focus align perfectly with our foundation's commitment to improving vascular health outcomes through evidence-based approaches and innovative solutions. 

The Foundation to Advance Vascular Cures continues to strengthen its leadership in vascular health advocacy and research through strategic appointments like Dr. Dashiell-Aje. Her addition to the Board of Directors reinforces our commitment to combining scientific expertise with patient-centered approaches to improve vascular health outcomes for all.

---

Important Note: Health-related information on this page, including text, graphics, images and other material is for educational purposes only and is not intended to be a substitute for professional medical advice, diagnosis or treatment. All opinions discussed in the PAD Facebook Group and Online Community are solely at the discretion of the administrators and community members and participants.

To learn more about Vascular Cures’ Patients as Partners Program, please visit: https://vascularcures.org/patients-as-partners/